It has been reported that CRC with loss of SMAD4 expression is associated with aggressive tumor behavior, poor prognosis and chemoresistance to 5-fluorouracil-based therapy, as well as decreased tumoral and peritumoral immune infiltration [59,66]. Here, SMAD4 is linked to neoplasm.